Management of Rh-Negative Newborn
The Rh-negative newborn itself requires no special management related to Rh status—the critical issue is determining if the baby is Rh-positive (which triggers maternal RhIG administration) and monitoring for hemolytic disease if the mother was previously sensitized.
Key Management Algorithm
1. Determine Newborn's Rh Status
- Obtain cord blood or neonatal blood sample for Rh typing 1
- This determines whether the mother needs postpartum RhIG prophylaxis
- If baby is Rh-negative like the mother, no RhIG is needed and no risk of hemolytic disease exists
2. Assess for Hemolytic Disease Risk
Do NOT routinely perform cord blood direct antiglobulin test (DAT/Coombs) 2:
- Routine antenatal anti-D prophylaxis causes frequent false-positive results
- Positive cord DAT poorly predicts subsequent hyperbilirubinemia
- British Committee for Standards in Haematology now recommends against routine cord blood DAT 2
Instead, use clinical monitoring:
- Monitor bilirubin levels using transcutaneous or serum measurements
- Watch for signs of hemolysis: jaundice, anemia, hepatosplenomegaly
- Only if mother has documented anti-D antibodies (sensitized) should you anticipate hemolytic disease 3
3. If Mother Was Sensitized (Has Anti-D Antibodies)
The Rh-positive newborn of a sensitized mother requires:
- Hemoglobin and hematocrit at birth
- Serial bilirubin monitoring (higher risk of hyperbilirubinemia: 39% vs 23% in controls) 3
- Phototherapy as needed (97.5% of affected infants require it) 4
- Exchange transfusion if severe (61.2% of severely affected infants need this) 4
- Top-up transfusions for ongoing anemia (28.8% require during NICU stay) 4
- Monitor for neonatal cholestasis with elevated conjugated bilirubin 4
4. Maternal RhIG Administration Decision
If baby is Rh-positive and mother is unsensitized:
- Administer RhIG to mother within 72 hours postpartum 1
- Standard dose: 300 mcg (1500 IU)
- Screen for excess fetomaternal hemorrhage using Kleihauer-Betke or flow cytometry—NOT fetal rosette test if baby has weak D phenotype (47% of labs incorrectly use rosette test, risking false negatives) 5
Critical Pitfalls to Avoid
The Weak D Phenotype Problem
- 28% of laboratories inappropriately perform antiglobulin testing on weak D specimens, sometimes leading to incorrect decisions against RhIG 5
- If immediate-spin is negative, give RhIG—do not perform additional testing that may confuse the picture 5
- Consider RHD genotyping in ambiguous cases (60% of labs now use this) 5
False Positive Coombs from Maternal Prophylaxis
- 20% of Rh-positive babies born to mothers receiving antenatal RhIG have positive DAT 6
- This does NOT cause neonatal hemolysis 6
- Do not overtreat based on positive DAT alone—use clinical signs and bilirubin levels 2, 6
Increased Risks in Rh-Negative Pregnancies
Even without sensitization, Rh-negative mothers have higher rates of 3:
- Neonatal hyperbilirubinemia (39% vs 23%)
- Low birth weight (11% vs 2%)
- NICU admission (30% vs 18%)
- Monitor these babies more closely regardless of sensitization status
Special Considerations
If mother received anti-D immunoglobulin and baby has hyperbilirubinemia:
- Resolution is actually faster with maternal RhIG administration (1 day vs 5 days median) 3
- This suggests the positive DAT from passive antibody transfer does not worsen outcomes
Obesity consideration:
- Standard RhIG dosing may fail in obese patients (BMI >35) 7
- Consider higher vigilance or alternative dosing strategies in this population